The present study investigated the role of the Simpson grade system, MIB-1 immunohistochemical marker, meningioma location and grade in the risk of recurrence. Between January, 2008 and January, 2018, the present study retrospectively evaluated all patients undergoing craniotomy for the resection of a histopathologically confirmed meningioma. Patients with neurofibromatosis, acoustic neurinomas and radiation treatment prior to surgery were excluded. After applying the exclusion criteria, 103 patients were included in the study. Following a mean follow-up period of 67.3±33 months, there were 12 cases (11.6%) of tumor recurrence. No significant association between meningioma recurrence and age, sex, or tumor location was found. When comparing the risk of recurrence between Simpson grades I, II, III and IV excisions, and between Simpson grade V, the difference was statistically significant. When comparing WHO grade I and II meningioma vs. grade III, the difference was significant. MIB-1 LI >3% exhibited a trend towards a significant association with the risk of recurrence. On the whole, the present study demonstrates that the Simpson grade is associated with the risk of recurrence. Patients with tumors with an MIB-1 index >3% may also be at a risk of recurrence. Notably, the present study proposed that in the case of recurrence, this is more likely to occur in an interval of 5.5 years following surgical intervention.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11707641PMC
http://dx.doi.org/10.3892/mi.2024.213DOI Listing

Publication Analysis

Top Keywords

risk recurrence
20
simpson grade
12
recurrence
9
mib-1 >3%
8
grade
6
meningioma
5
study
5
risk
5
prognostic factors
4
factors recurrence
4

Similar Publications

Importance: Endocrine treatments, such as Tamoxifen (TAM) and/or Aromatase inhibitors (AI), are the adjuvant therapy of choice for hormone-receptor positive breast cancer. These agents are associated with menopausal symptoms, adversely affecting drug compliance. Topical estrogen (TE) has been proposed for symptom management, given its' local application and presumed reduced bioavailability, however its oncological safety remains uncertain.

View Article and Find Full Text PDF

Background: Excisional hemorrhoidectomy and stapled hemorrhoidopexy are 2 common procedures for treating symptomatic hemorrhoids. However, concerns persist regarding the risk of postoperative complications and their unclear prevalence in the literature. This systematic review aims to evaluate and compare the prevalence of incontinence after stapled hemorrhoidopexy and excisional hemorrhoidectomy.

View Article and Find Full Text PDF

Aggressive angiomyxoma of the vagina: A case report and literature review.

Medicine (Baltimore)

January 2025

Department of Internal Medicine, Division of Hematology and Oncology, Jeonbuk National University Hospital, Jeonbuk National University Medical School, Jeonju, Republic of Korea.

Rationale: Aggressive angiomyxoma (AAM) is an exceptionally rare mesenchymal tumor that predominantly manifests in the female genital organs during the reproductive age. Its rarity alone makes it a fascinating subject for study. The diagnosis of AAM necessitates differentiation from other benign or mesenchymal tumors and can be confirmed through immunohistochemistry (IHC) staining.

View Article and Find Full Text PDF

Imaging characteristics and treatment of recurrent germinoma.

J Neurosurg

January 2025

1Department of Neurosurgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima; and.

Objective: An MRI protocol for germinoma surveillance after complete remission has not been established. Moreover, the standard treatment for recurrent or refractory germinoma has not been determined. In this study, the authors explored the imaging characteristics of recurrent germinoma and discuss their institution's experience with multidisciplinary treatment of this malignancy.

View Article and Find Full Text PDF

Purpose: To investigate whether hormone receptor-positive, human epidermal growth factor receptor 2-low (HR+HER2-low) versus HR+HER2-zero early breast cancers have distinct genomic and clinical characteristics.

Methods: This study included HR+, HER2-negative early breast cancers from patients enrolled in the phase III, randomized BIG 1-98 and SOFT clinical trials that had undergone tumor genomic sequencing. Tumors were classified HR+HER2-low if they had a centrally reviewed HER2 immunohistochemistry (IHC) score of 1+ or 2+ with negative in situ hybridization and HR+HER2-zero if they had an HER2 IHC score of 0.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!